Jeudi, 4 décembre – 11:00 à 12:00
Séminaire d’ Hanna Kulyk
Mass Spectrometry Imaging (MSI) for Comprehensive Metabolomic Studies: Leveraging the Platform’s Capabilities
Mass Spectrometry Imaging (MSI) is a powerful tool that brings together spatial and molecular data to map the distribution of metabolites in tissue samples. By creating detailed metabolic profiles across different areas of a tissue, MSI gives us a better understanding of the complexity of biological systems, the diversity of metabolic activity, and important functional pathways.
At the MetaToul platform, MSI is a key part of many research projects, showcasing its versatility and scientific value. The platform uses both MALDI and DESI MSI—two complementary techniques that differ in things like sensitivity, sample prep, and spatial resolution. Together, these methods provide a comprehensive view of metabolism, helping us gain deeper insights into how biological systems are regulated at the molecular level.
During this presentation, an overview and explanation of these two methods will be provided, and three use cases—host-microbe interactions, health, and biocatalysis—will be illustrated.
Jeudi, 11 décembre- 11h
Séminaire de Giuseppe Ronzitti (INSERM research director, GENETHON)
“Overcoming Adeno-Associated Virus (AAV) gene therapy limitations: an integrated approach”
Dr. Giuseppe Ronzitti leads a team of over 30 members—including university professors, tenured researchers, postdocs, PhD students, and technicians—focused on developing AAV gene therapy strategies for rare genetic diseases. Since 2018, he has headed the Immunology and Liver Gene Transfer (IMF) team at Genethon and, since 2019, serves as a tenured INSERM Research Director affiliated with UMR_S951 “INTEGRARE.”
Dr. Ronzitti has authored over 85 publications, including original research, reviews, and book chapters, with a cumulative impact factor of ~720 and~4,900 citations. He holds 21 patents in AAV-based gene therapy, eight of which are granted and five licensed to biotech companies.
He coordinated the CureCN project supporting a Crigler-Najjar syndrome clinical trial (now in Phase III, NCT03466463), and oversees another clinical program recently initiated, along with preclinical development of three AAV therapies for metabolic diseases. His team is structured into three research areas—Metabolic Diseases, AAV Technology, and Immunology—each led by senior scientists.
Over the past five years, Dr. Ronzitti has secured over €4 million in competitive funding from European, national, and private sources.
Friday 12/12, 11am, amphi Riquet
Philippe Schmitt-Kopplin (Ambassadeur CNRS Chimie);
He will talk about metabolomic of stars (celestial bodies, not Taylor Swift)
Vendredi, 19 décembre entre 08:30 à 10:30
